Cyberonics' Ambitious 5-Year Plan: Double Sales With New VNS Components
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics aims to double its sales to $320 million over the next five years by improving and adding new features to its VNS Therapy vagus nerve stimulation implant and entering new markets like Japan
You may also be interested in...
Business News In Brief
Roche snaps up BioImagene: Digital pathology laboratory equipment maker BioImagene is acquired by diagnostics firm Roche for $100 million under an agreement announced Aug. 23. BioImagene systems generate high-resolution, whole-slide digital images from glass microscope slides and incorporate software for image analysis. The deal builds on Roche's $3.4 billion acquisition in 2008 of tissue-based cancer test maker Ventana Medical Systems (1"The Gray Sheet" Jan. 28, 2008). By adding privately held BioImagene, Roche/Ventana "is uniquely positioned to improve laboratory efficiency and help pathologists improve patient care," the company said. "With BioImagene's current and future products, we will be able to deliver an end-to-end solution from automated staining to comprehensive patient reports.
Business News In Brief
Roche snaps up BioImagene: Digital pathology laboratory equipment maker BioImagene is acquired by diagnostics firm Roche for $100 million under an agreement announced Aug. 23. BioImagene systems generate high-resolution, whole-slide digital images from glass microscope slides and incorporate software for image analysis. The deal builds on Roche's $3.4 billion acquisition in 2008 of tissue-based cancer test maker Ventana Medical Systems (1"The Gray Sheet" Jan. 28, 2008). By adding privately held BioImagene, Roche/Ventana "is uniquely positioned to improve laboratory efficiency and help pathologists improve patient care," the company said. "With BioImagene's current and future products, we will be able to deliver an end-to-end solution from automated staining to comprehensive patient reports.
Cyberonics' VNS Therapy gains approval in Japan
Cyberonics plans to launch its VNS Therapy vagus nerve stimulation device in Japan for drug-resistant epilepsy once it receives final reimbursement authorization, the company said in announcing marketing clearance from Japan's Ministry of Health, Labor and Welfare on Jan. 19. The Japanese market entry is part of Cyberonics' plan to double sales within five years, the company said last month (1"The Gray Sheet" Dec. 14, 2009)